Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where authors phrase all words ' ALBECK M' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 40 riferimenti
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. Kalechman, Y; Longo, DL; Catane, R; Shani, A; Albeck, M; Sredni, B
      Synergistic anti-tumoral effect of paclitaxel (taxol)+AS101 in a murine model of B16 melanoma: Association with Ras-dependent signal-transduction pathways

      INTERNATIONAL JOURNAL OF CANCER
    2. Kalechman, Y; Strassmann, G; Albeck, M; Sredni, B
      Up-regulation by ammonium trichloro(dioxoethylene-0,0 ') tellurate (AS101)of Fas/Apo-1 expression on b16 melanoma cells: Implications for the antitumor effects of AS101. (vol 161, pg 3536, 1998)

      JOURNAL OF IMMUNOLOGY
    3. KALECHMAN Y; GAFTER U; ALBECK M; SREDNI B
      DELAY IN THE ONSET OF SLE FOLLOWING TREATMENT WITH THE IMMUNOMODULATOR AS101 - ASSOCIATION WITH IL-10 INHIBITION AND INCREASE IN TNF-ALPHA LEVELS

      European cytokine network
    4. KALECHMAN Y; STRASSMANN G; ALBECK M; SREDNI B
      UP-REGULATION BY AMMONIUM TRICHLORO(DIOXOETHYLENE-0,0')TELLURATE (AS101) OF FAS APO-1 EXPRESSION ON B16 MELANOMA-CELLS - IMPLICATIONS FOR THE ANTITUMOR EFFECTS OF AS101/

      The Journal of immunology (1950)
    5. ALBECK A; WEITMAN H; SREDNI B; ALBECK M
      TELLURIUM COMPOUNDS - SELECTIVE-INHIBITION OF CYSTEINE PROTEASES AND MODEL REACTION WITH THIOLS

      Inorganic chemistry
    6. ROSENBLATTBIN H; KALECHMAN Y; VONSOVER A; XU RH; DA JP; SHALIT F; HUBERMAN M; KLEIN A; STRASSMANN G; ALBECK M; SREDNI B
      THE IMMUNOMODULATOR AS101 RESTORES T-H1 TYPE OF RESPONSE SUPPRESSED BY BABESIA-RODHAINI IN BALB C MICE/

      Cellular immunology (Print)
    7. COJOCARU M; ELYASHIV I; ALBECK M
      MASS-SPECTROMETRIC STUDY OF SOME ORGANOTELLURIUM(IV) COMPOUNDS

      Journal of mass spectrometry.
    8. KALECHMAN Y; GAFTER U; ALBECK M; SREDNI B
      SUPPRESSION OF INTERLEUKIN-10 BY THE IMMUNOMODULATOR AS101 INHIBITS DEVELOPMENT OF AUTOANTIBODIES AND GLOMERULONEPHRITIS IN SYSTEMIC LUPUS-ERYTHEMATOSUS (SLE)

      Journal of the American Society of Nephrology
    9. KALECHMAN Y; CATANE R; ALBECK M; SREDNI B
      MECHANISM OF THE ANTITUMOR EFFECT OF THE IMMUNOMODULATOR AS101 AND PREVENTION BY AS101 OF BONE-MARROW TOXICITY WHEN ADMINISTERED WITH TAXOL

      Experimental hematology
    10. ELYASHIV I; GOLDSCHMIDT Z; BENARIE I; APED P; COJOCARU M; GOTTLIEB HE; ALBECK M
      SYNTHESIS AND STRUCTURE OF NOVEL HETEROCYCLIC AMINOTELLURANES

      Polyhedron
    11. KALECHMAN Y; GAFTER U; DA JP; ALBECK M; ALARCONSEGOVIA D; SREDNI B
      DELAY IN THE ONSET OF SYSTEMIC LUPUS-ERYTHEMATOSUS FOLLOWING TREATMENT WITH THE IMMUNOMODULATOR AS101 - ASSOCIATION WITH IL-10 INHIBITION AND INCREASE IN TNF-ALPHA LEVELS

      The Journal of immunology
    12. XU RH; KALECHMAN Y; ALBECK M; KUNG HF; SREDNI B
      INHIBITION OF B16 MELANOMA METASTASIS BY THE IMMUNOMODULATOR AS101

      International journal of oncology
    13. OLSEN KS; ALBECK M; AGERLIN N; SCHMIDT JF
      THE EFFECT OF KETANSERIN ON ICP AND CBF IN PATIENTS WITH NORMAL-PRESSURE HYDROCEPHALUS

      Journal of neurosurgical anesthesiology
    14. SREDNI B; TICHLER T; SHANI A; SHAPIRA J; BRUDERMAN I; ALBECK M; KALECHMAN Y
      BONE-MARROW SPARING AND PREVENTION OF ALOPECIA BY AS101 IN A RANDOMIZED PHASE-II STUDY ON NSCL CANCER-PATIENTS TREATED WITH CARBOPLATIN ANDETOPOSIDE

      Experimental hematology
    15. KALECHMAN Y; TICHLER T; SHANI A; ALBECK M; SREDNI B
      DIFFERENTIAL EFFECT OF THE IMMUNOMODULATOR AS101 ON B7-1 AND B7-2 COSTIMULATORY MOLECULES - ROLE IN TH1 PREDOMINANCE AND IN THE ANTITUMORALEFFECTS OF AS101

      Experimental hematology
    16. KALECHMAN Y; SHANI A; DOVRAT S; WHISNANT JK; METTINGER K; ALBECK M; SREDNI B
      THE ANTITUMORAL EFFECT OF THE IMMUNOMODULATOR AS101 AND PACLITAXEL (TAXOL) IN A MURINE MODEL OF LUNG ADENOCARCINOMA

      The Journal of immunology
    17. SREDNI B; XU RH; ALBECK M; GAFTER U; GAL R; SHANI A; TICHLER T; SHAPIRA J; BRUDERMAN I; CATANE R; KAUFMAN B; WHISNANT JK; METTINGER KL; KALECHMAN Y
      THE PROTECTIVE ROLE OF THE IMMUNOMODULATOR AS101 AGAINST CHEMOTHERAPY-INDUCED ALOPECIA STUDIES ON HUMAN AND ANIMAL-MODELS

      International journal of cancer
    18. SREDNI B; TICHLER T; SHANI A; CATANE R; KAUFMAN B; STRASSMANN G; ALBECK M; KALECHMAN Y
      PREDOMINANCE OF TH1 RESPONSE IN TUMOR-BEARING MICE AND CANCER-PATIENTS TREATED WITH AS101

      Journal of the National Cancer Institute
    19. XU RH; KALECHMAN Y; ALBECK M; SREDNI B
      THE CYTOPROTECTIVE EFFECT OF THE IMMUNOMODULATOR AS101 AGAINST HYDROCHLORIDE INDUCED GASTRIC-LESIONS

      Research communications in molecular pathology and pharmacology
    20. TICHLER T; KAUFMAN B; HENKIN Y; SHANI A; ALBECK M; SREDNI B
      MESOTHELIOMA - TREATMENT WITH A NEW IMMUNOMODULATOR AS101

      European journal of cancer
    21. SREDNI B; ALBECK M; TICHLER T; SHANI A; SHAPIRA J; BRUDERMAN I; CATANE R; KAUFMAN B; KALECHMAN Y
      BONE MARROW-SPARING AND PREVENTION OF ALOPECIA BY AS1O1 IN NON-SMALL-CELL LUNG-CANCER PATIENTS TREATED WITH CARBOPLATIN AND ETOPOSIDE

      Journal of clinical oncology
    22. KALECHMAN Y; SHANI A; DOVRAT S; ALBECK M; BRUCKNER HW; SREDNI B
      SYNERGISTIC ANTITUMOR EFFECT OF THE IMMUNOMODULATOR ASIOI AND TAXOL IN EXPERIMENTAL MURINE MODEL

      Experimental hematology
    23. SREDNI B; SHANI A; SHAPIRA J; BRUDERMAN I; ALBECK M; KALECHMAN Y; TICHLER T
      BONE-MARROW SPARING AND PREVENTION OF ALOPECIA BY ASIOI IN A RANDOMIZED PHASE-II STUDY ON NSCL CANCER-PATIENTS TREATED WITH CARBOPLATIN ANDVP-16

      Experimental hematology
    24. KALECHMAN Y; RUSHKIN G; NERUBAY J; ALBECK M; SREDNI B
      EFFECT OF THE IMMUNOMODULATOR AS101 ON CHEMOTHERAPY-INDUCED MULTILINEAGE MYELOSUPPRESSION, THROMBOCYTOPENIA, AND ANEMIA IN MICE

      Experimental hematology
    25. KALECHMAN Y; SHANI A; ALBECK M; SREDNI B
      INDUCTION OF ACUTE-PHASE PROTEINS IN MICE AND HUMANS BY TREATMENT WITH AS101, AN IMMUNOMODULATOR WITH RADIOPROTECTIVE PROPERTIES

      Immunopharmacology
    26. KALECHMAN Y; ZULOFF A; ALBECK M; STRASSMANN G; SREDNI B
      ROLE OF ENDOGENOUS CYTOKINES SECRETION IN RADIOPROTECTION CONFERRED BY THE IMMUNOMODULATOR AMMONIUM TRICHLORO(DIOXYETHYLENE-0-0')TELLURATE

      Blood
    27. SREDNI B; ZULOFF A; ALBECK M; KALECHMAN Y
      THE ROLE OF INTERLEUKIN-1 (IL-1), TUMOR-NECROSIS-FACTOR (TNF) AND INTERLEUKIN-6 (IL-6) IN THE RADIOPROTECTIVE PROPERTIES EXERTED BY AMMONIUM TRICHLORO(DIOXYETHYLENE-O-O')TELLURATE (AS101)

      Experimental hematology
    28. SREDNI B; SHAPIRO Y; SHANI A; BRUDERMAN Y; CATANE R; KAUFMAN B; PAVLOTSKY F; KALECHMAN Y; ALBECK M; TICHLER T
      HAIR PRESERVATION AND PLATELET GRANULOCYTE SPARING EFFECT USING AS101WITH CHEMOTHERAPY - A RANDOMIZED STUDY/

      Experimental hematology
    29. DASTGHEIB K; HIKITA N; SREDNI B; ALBECK M; SREDNI D; NUSSENBLATT RB; CHAN CC
      OCULAR INFLAMMATION STIMULATED BY THE IMMUNOMODULATOR AS101 [AMMONIUMTRICHLORO(DIOXYETHELENE-O-O') TELLURATE]

      Current eye research
    30. SREDNI B; ALBECK M; KALECHMAN Y
      INDUCTION OF ACUTE-PHASE PROTEINS IN MICE AND HUMANS BY TREATMENT WITH AS101, AND IMMUNOMODULATOR WITH RADIOPROTECTIVE PROPERTIES

      Hepatology
    31. GOTTLIEB HE; HOZ S; ELYASHIV I; ALBECK M
      LIGAND-EXCHANGE PROCESSES IN TETRAALKOXYTELLURANES

      Inorganic chemistry
    32. SREDNI B; SHAPIRO Y; SHANI A; BRUDERMAN Y; CATANE R; BRENNER H; KAUFMAN B; PAVLOTSKY F; KALECHMAN Y; FARBSTEIN M; ALBECK M; TICHLER T
      HAIR PRESERVATION AND PLATELET GRANULOCYTE SPARING EFFECT USING AS101WITH CHEMOTHERAPY - A RANDOMIZED STUDY/

      Experimental hematology
    33. SREDNI B; ZULOFF A; ALBECK M; KALECHMAN Y
      THE ROLE OF INTERLEUKIN-1 (IL-1), TUMOR-NECROSIS-FACTOR (TNF) AND INTERLEUKIN-6 (IL-6) IN THE RADIOPROTECTIVE PROPERTIES EXERTED BY AMMONIUM TRICHLORO(DIOXYETHYLENE-O-O')TELLURATE (AS101)

      Experimental hematology
    34. KALECHMAN Y; LEDERER G; ALBECK M; SREDNI B
      PREVENTION OF TOXICITY TO CIRCULATING BLOOD-ELEMENTS IN CHEMOTHERAPY TREATED MICE BY THE IMMUNOMODULATOR AMMONIUM TRICHLORO(DIOXYETHYLENE-O-O')TELLURATE (AS101)

      Experimental hematology
    35. KALECHMAN Y; GAFTER U; BARKAI IS; ALBECK M; SREDNI B
      MECHANISM OF RADIOPROTECTION CONFERRED BY THE IMMUNOMODULATOR AS101

      Experimental hematology
    36. KALECHMAN Y; SHANI A; ALBECK M; BARKAI IS; SREDNI B
      INCREASED DNA-REPAIR ABILITY AFTER IRRADIATION FOLLOWING TREATMENT WITH THE IMMUNOMODULATOR AS101

      Radiation research
    37. KALECHMAN Y; SOTNIKBARKAI I; ALBECK M; SREDNI B
      THE PROTECTIVE ROLE OF AS101 IN COMBINATION WITH CYTOTOXIC DRUGS ACTING BY VARIOUS MECHANISMS OF ACTION

      The Journal of immunology
    38. SREONI B; SHAPIRO Y; SHANI A; BRUDERMAN Y; CATANE R; BRENNER H; KAUFMAN B; PAVLOTSKY F; KALECHMAN Y; FARBSTEIN M; ALBECK M; TICHLEI T
      HAIR PRESERVATION AND PLATELET GRANULOCYTE SPARING EFFECT USING AS101WITH CHEMOTHERAPY - A RANDOMIZED STUDY

      The Journal of immunology
    39. KALECHMAN Y; SOTNIKBARKAI I; ALBECK M; SREDNI B
      PROTECTION OF BONE-MARROW STROMAL CELLS FROM THE TOXIC EFFECTS OF CYCLOPHOSPHAMIDE INVIVO AND OF ASTA-Z 7557 AND ETOPOSIDE INVITRO BY AMMONIUM TRICHLORO(DIOXYETHYLENE-O-O')TELLURATE (AS101)

      Cancer research
    40. KALECHMAN Y; SHANI A; SOTNIKBARKAI I; ALBECK M; SREDNI B
      THE PROTECTIVE ROLE OF AMMONIUM TRICHLORO(DIOXOETHYLENE-O,O')TELLURATE IN COMBINATION WITH SEVERAL CYTOTOXIC DRUGS ACTING BY DIFFERENT MECHANISMS OF ACTION

      Cancer research


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 23/01/21 alle ore 00:18:06